vorinostat has been researched along with Carcinoma, Epidermoid in 28 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients." | 2.73 | Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. ( Blumenschein, GR; Chen, C; Chiao, JH; Frankel, SR; Kies, MS; Kumar, AJ; Lu, C; Papadimitrakopoulou, VA; Ricker, JL, 2008) |
| "Esophageal cancers are highly aggressive tumors with poor prognosis despite some recent advances in surgical and radiochemotherapy treatment options." | 1.42 | Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. ( Ahrens, TD; Boerries, M; Busch, H; Follo, M; Hembach, S; Hoeppner, J; Hopt, UT; Lassmann, S; Ostendorp, J; Timme, S; Werner, M, 2015) |
| " Carfilzomib and its orally bioavailable structural analog oprozomib are second-generation, highly-selective, proteasome inhibitors." | 1.40 | Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. ( Johnson, DE; Kirk, CJ; Zang, Y, 2014) |
| "Vorinostat is a potent HDAC inhibitor and has shown potential to inhibit growth of human xenograft tumors." | 1.39 | Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. ( Athar, M; Ballestas, ME; Chaudhary, SC; Elmets, CA; Kopelovich, L; Kurundkar, D; Srivastava, RK, 2013) |
| "Effective targeted therapeutics for squamous cell carcinoma (SCC) are lacking." | 1.39 | Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. ( Benes, CH; Ellisen, LW; Forster, N; Garnett, MJ; Greninger, P; He, L; McDermott, U; Ramakrishnan, S; Rothenberg, SM; Torres-Lockhart, K, 2013) |
| "Head and neck squamous cell carcinoma cell lines, human keratinocyte and HNSCC xenograft models were treated with histone deacetylase inhibitors (HDACIs) and new generation PI3K and dual PI3K-mTOR inhibitors either alone or in combination." | 1.38 | Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. ( Cameron, S; Dahler, A; de Long, LM; Endo-Munoz, L; Erlich, RB; Guminski, A; Hazar-Rethinam, M; Kherrouche, Z; Rickwood, D; Saunders, NA; Wooley, K, 2012) |
| "This combined therapeutic effect on esophageal cancer epithelial-mesenchymal transition was associated with upregulation of E-cadherin protein expression." | 1.36 | Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells. ( Jones, DR; Liu, Y; Nagji, AS; Taylor, MD; Theodosakis, N, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 18 (64.29) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Lamblin, M | 1 |
| Dabbas, B | 1 |
| Spingarn, R | 1 |
| Mendoza-Sanchez, R | 1 |
| Wang, TT | 1 |
| An, BS | 1 |
| Huang, DC | 1 |
| Kremer, R | 1 |
| White, JH | 1 |
| Gleason, JL | 1 |
| Zagni, C | 1 |
| Pistarà, V | 1 |
| Oliveira, LA | 1 |
| Castilho, RM | 1 |
| Romeo, G | 1 |
| Chiacchio, U | 1 |
| Rescifina, A | 1 |
| Krieger, V | 1 |
| Hamacher, A | 1 |
| Cao, F | 1 |
| Stenzel, K | 1 |
| Gertzen, CGW | 1 |
| Schäker-Hübner, L | 1 |
| Kurz, T | 1 |
| Gohlke, H | 1 |
| Dekker, FJ | 1 |
| Kassack, MU | 1 |
| Hansen, FK | 1 |
| Akhlaq, R | 1 |
| Khan, T | 1 |
| Ahmed, T | 1 |
| Musharraf, SG | 1 |
| Ali, A | 1 |
| Tanaka, N | 1 |
| Patel, AA | 1 |
| Tang, L | 1 |
| Silver, NL | 1 |
| Lindemann, A | 1 |
| Takahashi, H | 1 |
| Jaksik, R | 1 |
| Rao, X | 1 |
| Kalu, NN | 1 |
| Chen, TC | 1 |
| Wang, J | 2 |
| Frederick, MJ | 1 |
| Johnson, F | 1 |
| Gleber-Netto, FO | 1 |
| Fu, S | 1 |
| Kimmel, M | 1 |
| Hittelman, WN | 1 |
| Pickering, CR | 1 |
| Myers, JN | 1 |
| Osman, AA | 1 |
| Zang, Y | 1 |
| Kirk, CJ | 1 |
| Johnson, DE | 1 |
| Ahrens, TD | 1 |
| Timme, S | 1 |
| Hoeppner, J | 1 |
| Ostendorp, J | 1 |
| Hembach, S | 1 |
| Follo, M | 1 |
| Hopt, UT | 1 |
| Werner, M | 1 |
| Busch, H | 1 |
| Boerries, M | 1 |
| Lassmann, S | 1 |
| Datta, J | 1 |
| Islam, M | 1 |
| Dutta, S | 1 |
| Roy, S | 1 |
| Pan, Q | 1 |
| Teknos, TN | 1 |
| Nagumo, T | 1 |
| Takaoka, S | 1 |
| Yoshiba, S | 1 |
| Ohashi, M | 1 |
| Shirota, T | 1 |
| Hatori, M | 1 |
| Isobe, T | 1 |
| Tachikawa, T | 1 |
| Shintani, S | 1 |
| Suzuki, M | 3 |
| Endo, M | 1 |
| Shinohara, F | 3 |
| Echigo, S | 3 |
| Rikiishi, H | 3 |
| Owonikoko, TK | 1 |
| Ramalingam, SS | 1 |
| Kanterewicz, B | 1 |
| Balius, TE | 1 |
| Belani, CP | 1 |
| Hershberger, PA | 1 |
| Yeh, CC | 1 |
| Deng, YT | 1 |
| Sha, DY | 1 |
| Hsiao, M | 1 |
| Kuo, MY | 1 |
| Taylor, MD | 1 |
| Liu, Y | 1 |
| Nagji, AS | 1 |
| Theodosakis, N | 1 |
| Jones, DR | 2 |
| Shim, SH | 1 |
| Lee, CT | 1 |
| Lee, JJ | 1 |
| Kim, SY | 1 |
| Hah, JH | 1 |
| Heo, DS | 1 |
| Sung, MW | 1 |
| Schwartz, BE | 1 |
| Hofer, MD | 1 |
| Lemieux, ME | 1 |
| Bauer, DE | 1 |
| Cameron, MJ | 1 |
| West, NH | 1 |
| Agoston, ES | 1 |
| Reynoird, N | 1 |
| Khochbin, S | 1 |
| Ince, TA | 1 |
| Christie, A | 1 |
| Janeway, KA | 1 |
| Vargas, SO | 1 |
| Perez-Atayde, AR | 1 |
| Aster, JC | 1 |
| Sallan, SE | 1 |
| Kung, AL | 1 |
| Bradner, JE | 1 |
| French, CA | 1 |
| Bruzzese, F | 1 |
| Leone, A | 1 |
| Rocco, M | 1 |
| Carbone, C | 1 |
| Piro, G | 1 |
| Caraglia, M | 1 |
| Di Gennaro, E | 1 |
| Budillon, A | 1 |
| Bai, LY | 1 |
| Chiu, CF | 1 |
| Pan, SL | 1 |
| Sargeant, AM | 1 |
| Shieh, TM | 1 |
| Wang, YC | 1 |
| Weng, JR | 1 |
| Erlich, RB | 1 |
| Kherrouche, Z | 1 |
| Rickwood, D | 1 |
| Endo-Munoz, L | 1 |
| Cameron, S | 1 |
| Dahler, A | 1 |
| Hazar-Rethinam, M | 1 |
| de Long, LM | 1 |
| Wooley, K | 1 |
| Guminski, A | 1 |
| Saunders, NA | 1 |
| Li, J | 1 |
| Gong, C | 1 |
| Feng, X | 1 |
| Zhou, X | 1 |
| Xu, X | 1 |
| Xie, L | 1 |
| Wang, R | 1 |
| Zhang, D | 1 |
| Wang, H | 1 |
| Deng, P | 1 |
| Zhou, M | 1 |
| Ji, N | 1 |
| Zhou, Y | 1 |
| Wang, Y | 1 |
| Wang, Z | 3 |
| Liao, G | 1 |
| Geng, N | 1 |
| Chu, L | 1 |
| Qian, Z | 1 |
| Chen, Q | 2 |
| Moskaluk, CA | 1 |
| Gillenwater, HH | 1 |
| Petroni, GR | 1 |
| Burks, SG | 1 |
| Philips, J | 1 |
| Rehm, PK | 1 |
| Olazagasti, J | 1 |
| Kozower, BD | 1 |
| Bao, Y | 1 |
| Kurundkar, D | 1 |
| Srivastava, RK | 1 |
| Chaudhary, SC | 1 |
| Ballestas, ME | 1 |
| Kopelovich, L | 1 |
| Elmets, CA | 1 |
| Athar, M | 1 |
| He, L | 1 |
| Torres-Lockhart, K | 1 |
| Forster, N | 1 |
| Ramakrishnan, S | 1 |
| Greninger, P | 1 |
| Garnett, MJ | 1 |
| McDermott, U | 1 |
| Rothenberg, SM | 1 |
| Benes, CH | 1 |
| Ellisen, LW | 1 |
| Zhang, Y | 2 |
| Jung, M | 2 |
| Dritschilo, A | 1 |
| Sato, T | 1 |
| Sato, Y | 1 |
| Shen, J | 1 |
| Huang, C | 1 |
| Jiang, L | 1 |
| Gao, F | 1 |
| Bai, J | 1 |
| Zhou, H | 1 |
| Blumenschein, GR | 1 |
| Kies, MS | 1 |
| Papadimitrakopoulou, VA | 1 |
| Lu, C | 1 |
| Kumar, AJ | 1 |
| Ricker, JL | 1 |
| Chiao, JH | 1 |
| Chen, C | 1 |
| Frankel, SR | 1 |
| Nishimura, K | 1 |
| Gillenwater, AM | 1 |
| Zhong, M | 1 |
| Lotan, R | 1 |
2 trials available for vorinostat and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2012 |
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Capsules; Car | 2008 |
26 other studies available for vorinostat and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Histone Deace | 2010 |
Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Proliferation; Dose-Response Relationship, Dru | 2017 |
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Squamous Cell; Cell Prol | 2019 |
PX-12 synergistically enhances the therapeutic efficacy of vorinostat under hypoxic tumor microenvironment in oral squamous cell carcinoma in vitro.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Disulfides; Head and Neck Neoplasms; Histone Deacetylase | 2023 |
Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferat | 2017 |
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, S | 2014 |
Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Topics: Acetylation; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; | 2015 |
Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Genes, Tumor | 2016 |
Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p21; Dru | 2009 |
Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Topics: Apoptosis; Carcinoma, Squamous Cell; Caspase 12; Caspase Inhibitors; Caspases, Initiator; Cell Line, | 2009 |
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.
Topics: Acetylation; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemothera | 2010 |
Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression.
Topics: Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Drug Synergism | 2009 |
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezo | 2010 |
A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC.
Topics: Adenoviridae; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Coxsackie and Adeno | 2010 |
Differentiation of NUT midline carcinoma by epigenomic reprogramming.
Topics: Acetylation; Animals; Carcinoma, Squamous Cell; Cell Differentiation; Child; Female; Gene Knockdown | 2011 |
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Li | 2011 |
Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase 6 | 2011 |
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; Head and | 2012 |
Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell L | 2012 |
Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Cell Surviv | 2013 |
Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Carcinoma, S | 2013 |
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Depsipeptides; Dos | 2004 |
Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Caspases; Cell Cycle; Cell Line, Tumor; | 2007 |
Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cel | 2007 |
Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cisplatin; | 2007 |
Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
Topics: Acetylation; Apoptosis; Carcinoma, Squamous Cell; Caspases; Cell Adhesion; Cell Line, Tumor; Cell Pr | 2007 |